Matteo Ferro, Ottavio de Cobelli, Gennaro Musi, Francesco Del Giudice, Giuseppe Carrieri, Gian Maria Busetto, Ugo Giovanni Falagario, Alessandro Sciarra, Martina Maggi, Felice Crocetto, Biagio Barone, Vincenzo Francesco Caputo, Michele Marchioni, Giuseppe Lucarelli, Ciro Imbimbo, Francesco Alessandro Mistretta, Stefano Luzzago, Mihai Dorin Vartolomei, Luigi Cormio, Riccardo Autorino, Octavian Sabin Tătaru
{"title":"Radiomics in prostate cancer: an up-to-date review.","authors":"Matteo Ferro, Ottavio de Cobelli, Gennaro Musi, Francesco Del Giudice, Giuseppe Carrieri, Gian Maria Busetto, Ugo Giovanni Falagario, Alessandro Sciarra, Martina Maggi, Felice Crocetto, Biagio Barone, Vincenzo Francesco Caputo, Michele Marchioni, Giuseppe Lucarelli, Ciro Imbimbo, Francesco Alessandro Mistretta, Stefano Luzzago, Mihai Dorin Vartolomei, Luigi Cormio, Riccardo Autorino, Octavian Sabin Tătaru","doi":"10.1177/17562872221109020","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer (PCa) is the most common worldwide diagnosed malignancy in male population. The diagnosis, the identification of aggressive disease, and the post-treatment follow-up needs a more comprehensive and holistic approach. Radiomics is the extraction and interpretation of images phenotypes in a quantitative manner. Radiomics may give an advantage through advancements in imaging modalities and through the potential power of artificial intelligence techniques by translating those features into clinical outcome prediction. This article gives an overview on the current evidence of methodology and reviews the available literature on radiomics in PCa patients, highlighting its potential for personalized treatment and future applications.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/1d/10.1177_17562872221109020.PMC9260602.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562872221109020","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Prostate cancer (PCa) is the most common worldwide diagnosed malignancy in male population. The diagnosis, the identification of aggressive disease, and the post-treatment follow-up needs a more comprehensive and holistic approach. Radiomics is the extraction and interpretation of images phenotypes in a quantitative manner. Radiomics may give an advantage through advancements in imaging modalities and through the potential power of artificial intelligence techniques by translating those features into clinical outcome prediction. This article gives an overview on the current evidence of methodology and reviews the available literature on radiomics in PCa patients, highlighting its potential for personalized treatment and future applications.
期刊介绍：
Therapeutic Advances in Urology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of urology.
The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in urology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest across all areas of urology, including treatment of urological disorders, with a focus on emerging pharmacological therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
